1.Pecorelli S.Revised FIGO staging for carcinoma of the vulva，cervix，and endometrium.Int J Gynaecol Obstet，2009，105（2）：103-104.

2.Tabbaa ZM，Gonzalez J，Sznurkowski JJ，et al.Impact of the new FIGO 2009 staging classification for vulvar cancer on prognosis and stage distribution.Gynecol Oncol，2012，127（1）：147-152.

3.Levenback CF，Ali S，Coleman RL，et al.Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva：a gynecologic oncology group study.J Clin Oncol，2012，30（31）：3786-3791.

4.Berek JS，Hacker NF.Berek&Hacker's gynecologic oncology.Philadelphia：Wolters Kluwer/Lippincott Williams&Wilkins Health.6th ed.2014.

5.Stephan Polterauer，Richard Schwameis，Christoph Grimm，et al.Lymph node ratio in inguinal lymphadenectomy for squamous cell vulvar cancer：Results from the AGO-CaRE-1 study.Gynecol Oncol，2019，153：286-291.

6.Chapman PB，Robert C，Larkin J，et al.Vemurafenib in patients with BRAF V600 mutation-positive metastatic melanoma：final overall survival results of the randomized BRIM-3 study.Annals of Oncology，2017，28：2581-2587.

7.Caroline Robert， Antoni Ribas， Omid Hamid， et al.Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma.J Clin Oncol，2018，36（17）：1668-1674.